SV

Street Verdict

Analyst Scorecard

A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.

“Upgraded Biocon to a 'Buy' rating with a target price of ₹430 per share, emphasizing that the Malaysian site achieved 'Voluntary Action Indicated' (VAI) status, ensuring USFDA compliance for critical biosimilar production. The report projects a strong earnings trajectory, forecasting a 21% CAGR in EBITDA over FY25-27, and raised valuation for Biocon’s biologics business.”

Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%

BioconBullishCalled 14 Jan 2025Graded 14 Jan 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹430, as stated.

Window: 12 months, the default when no time frame is stated.

Neither the target ₹430 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹382.05 on 2025-01-15 (next trading session's close); neither target nor stop reached by window end 2026-01-14. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Biocon since this call

1-year tracking window
Read the original articleSee Motilal Oswal Analysis’s full track record